The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.
The main question\[s\] it aims to answer are:
1. Are patients with advanced lung disease able to tolerate semaglutide therapy? 2. Are we able to titrate semaglutide therapy to a target weight?
Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.
Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
Age > 18
BMI > 30 kg/m2
Requires supplemental oxygen on exertion
Diabetes
Pregnant or Breastfeeding
Recent weight loss
Recent or chronic GI complaints
Single group
Semaglutide Pen Injector
DrugOnce weekly subcutaneous injection
Tolerability
The proportion of participants who either reach a target semaglutide dose of 1.0 mg/week or who achieve target weight.
Body composition
Change in percent body fat
Body composition
Change in skeletal muscle index
Body composition
Change in weight
Lung function
Change in forced vital capacity
Click on the lead sponsor to view all of their trials.
